Zimmer Biomet Holdings (ZBH) EBITDA (2009 - 2026)

Zimmer Biomet Holdings has reported EBITDA for 18 years, with the latest figure at $326.1 million in Q2 2026.

• On a quarterly basis, EBITDA rose 8.7% year-over-year to $326.1 million in Q2 2026; TTM through Jun 2026 was $1.2 billion, a 4.42% decrease from a year earlier, with the FY2025 full-year figure at $1.1 billion, down 14.59% from the prior year.
• EBITDA was $326.1 million for Q2 2026 at Zimmer Biomet Holdings, down from $373.2 million in the prior quarter.
• The five-year high for EBITDA was $389.0 million in Q4 2024, with the low at -$28.3 million in Q4 2022.
• Average EBITDA over 5 years is $281.0 million, with a median of $296.2 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2023: EBITDA slumped 121.15% in 2022, then soared 1351.59% in 2023.
• Over 5 years, EBITDA stood at -$28.3 million in 2022, then jumped by 1351.59% to $354.2 million in 2023, then increased by 9.82% to $389.0 million in 2024, then plunged by 60.28% to $154.5 million in 2025, then jumped by 111.07% to $326.1 million in 2026.
• The last three EBITDA figures came in at $326.1 million (Q2 2026), $373.2 million (Q1 2026), and $154.5 million (Q4 2025), per Business Quant data.